Clinical Outcome of Cefiderocol for Infections with Carbapenem-Resistant Organisms

Cefiderocol is a novel cephalosporin recently approved by the FDA to aid clinicians in the fight against multidrug-resistant (including carbapenem-resistant) gram-negative organisms. The primary objective of this study is to evaluate the 14- and 28-day mortality associated with cefiderocol. We perfo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sajib, Monirul I., Monteforte, Melinda, Go, Roderick
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215264/
https://www.ncbi.nlm.nih.gov/pubmed/37237839
http://dx.doi.org/10.3390/antibiotics12050936

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10215264/
https://www.ncbi.nlm.nih.gov/pubmed/37237839
http://dx.doi.org/10.3390/antibiotics12050936

Ejemplares similares